Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
First Letter Of Last Name
is
Y
and
Author
is
Yulyana, Yulyana
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
R
Yulyana Y
,
Tovmasyan A
,
Ho IAw
,
Sia KChuan
,
Newman JP
,
Ng WHoe
,
Guo CMing
,
Hui KMan
,
Batinic-Haberle I
,
Lam PYp
.
Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.
Stem Cell Rev. 2015.
PubMed
Google Scholar
M
Ho IAW
,
Yulyana Y
,
Sia KC
,
Newman JP
,
Guo CM
,
Hui KM
,
Lam PYP
.
Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis.
FASEB J. 2014;28(10):4359-68.
PubMed
Google Scholar
C
Chong DQ
,
Toh XY
,
Ho IAw
,
Sia KC
,
Newman JP
,
Yulyana Y
,
Ng W-H
,
Lai SH
,
Ho MMf
,
Dinesh N
, et al.
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
BMC Cancer. 2015;15(1):255.
PubMed
Google Scholar